Clinical Trials Logo

Filter by:
NCT ID: NCT00836225 Completed - Clinical trials for Type 2 Diabetes Mellitus

Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in Healthy Volunteers

Start date: January 2009
Phase: Phase 1
Study type: Interventional

The primary purpose of this trial is to assess the safety and tolerability of ISIS-SGLT2Rx when given at increasing single doses and to assess the safety and tolerability of the same doses when given multiple times.

NCT ID: NCT00835770 Completed - Clinical trials for Relapsing-Remitting Multiple Sclerosis

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)

ENDORSE
Start date: February 3, 2009
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the long-term safety profile of BG00012 (dimethyl fumarate). Secondary objectives of this study are to evaluate the long-term efficacy of BG00012 using clinical endpoints and disability progression, to evaluate further the long-term effects of BG00012 on multiple sclerosis (MS) brain lesions on magnetic resonance imaging (MRI) scans in participants who had MRI scans as part of Studies 109MS301 (NCT00420212) and 109MS302 (NCT00451451) and to evaluate the long-term effects of BG00012 on health economics assessments and the visual function test.

NCT ID: NCT00835471 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)

NVALT10
Start date: March 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess if the combination of erlotinib and chemotherapy (docetaxel in case of squamous cell NSCLC or pemetrexed in case of other histological types) is superior to erlotinib alone and has acceptable tolerability and safety in the 2nd line treatment of patients with advanced/metastatic non-small cell lung cancer (NSCLC).

NCT ID: NCT00833612 Completed - Clinical trials for Acute Myocardial Infarction (AMI)

Counterpulsation Reduces Infarct Size Pre-PCI for AMI

CRISP-AMI
Start date: December 2008
Phase: Phase 4
Study type: Interventional

Subjects with anterior acute STEMI who receive an IABC before primary PCI will have decreased MI size.

NCT ID: NCT00833482 Completed - HIV Infections Clinical Trials

Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants

Start date: September 2009
Phase: Phase 1
Study type: Interventional

This study assesses the effects of voriconazole, 200 mg, administered twice daily (BID), on the steady-state pharmacokinetics of atazanavir administered as atazanavir/ritonavir, 300/100 mg once daily (QD), in healthy participants with functional CYP2C19 alleles. The study also reviews the effects of atazanavir/ritonavir, 300/100 mg QD, on the pharmacokinetics of voriconazole, 200 mg, BID in healthy participants with functional CYP2C19 alleles.

NCT ID: NCT00833248 Completed - Prostate Cancer Clinical Trials

Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer

Start date: April 2009
Phase: Phase 3
Study type: Interventional

The purpose of this phase 3B trial was to see how well a new trial drug (degarelix) works in terms of reducing the size of the prostate volume in prostate cancer patients who were scheduled to undergo subsequent radiotherapy for treatment of their prostate cancer. Prior to receiving radiotherapy, it is recommended that patients with intermediate to high risk prostate cancer are pre-treated with hormone therapy (so-called neoadjuvant therapy) which is known to reduce the size of the prostate and thereby decrease the required radiation field and enable a more safe and effective treatment. In this trial, participants were randomly selected (like flipping a coin) to receive either degarelix given alone or a standard hormone therapy (combination of goserelin and bicalutamide. The treatment was given for three months and the prostate size was measured by ultra sound at the beginning and at the end of the trial. The participants were required to come to the clinic for 5 or 6 visits during the three months.

NCT ID: NCT00833196 Completed - Clinical trials for Idiopathic Cervical Dystonia

Factors Influencing Response to One BoNT-A Injection Cycle in Subjects Suffering From Idiopathic Cervical Dystonia

Start date: February 2009
Phase:
Study type: Observational

A post marketing, international, multicenter, observational, prospective, longitudinal study. The purpose of the study is to describe cervical dystonia sub-types with their injection protocols and response to BoNT-A.

NCT ID: NCT00833001 Completed - Cystocele Clinical Trials

Clinical Performance of the GYNECARE PROLIFT + M* Pelvic Floor Repair System as a Device for Pelvic Organ Prolapse

Start date: April 2008
Phase: Phase 2/Phase 3
Study type: Observational

The purpose of this study is to evaluate the clinical performance of the PROLIFT system with a new lighter-weight mesh in repair of vaginal prolapse.

NCT ID: NCT00832156 Completed - Burns Clinical Trials

Application of Cultured Autologous Keratinocytes for Burn Wound Healing

KC
Start date: June 2008
Phase: Phase 3
Study type: Interventional

In this study the treatment of full thickness burn wounds with cultured autologous keratinocytes in combination with meshed split skin autograft versus meshed split skin graft alone will be compared. It is expected that the application of cultured autologous keratinocytes in combination with a meshed split skin autograft will improve wound healing and scar formation.

NCT ID: NCT00831857 Completed - Clinical trials for Renal Cell Carcinoma

VEGF Imaging in Renal Cell Carcinoma

Renimage
Start date: January 2009
Phase:
Study type: Observational

The primary objective of the study is to evaluate the feasibility of 89Zr-bevacizumab PET imaging as a biomarker before and during treatment with sunitinib or bevacizumab plus interferon in patients with RCC. 89Zr-bevacizumab PET imaging will be regarded a promising biomarker if the target for treatment (VEGF) can be visualised and if uptake changes after institution of treatment.